Related Experiment Videos
[New statistical criteria for validation of the antiarrhythmic effects by acute oral testing]
Insights
A new statistical model helps evaluate acute effects of antiarrhythmic drugs in patients with heart disease. The model predicts treatment effectiveness based on ventricular premature beat (VPB) reduction, aiding in patient response classification.
Area of Science:
- Cardiology
- Pharmacology
- Medical Statistics
Background:
- Assessing acute effects of antiarrhythmic agents after single oral doses is challenging.
- Patients with frequent complex ventricular premature beats (VPBs) and severe organic heart disease require effective treatment evaluation.
Purpose of the Study:
- To develop a new statistical model for evaluating acute antiarrhythmic drug effects.
- To establish reliable criteria for assessing patient response to antiarrhythmic therapy.
Main Methods:
- Analysis of Holter ECG data from 46 patients with severe heart disease.
- Utilized nine 10-hour and two 24-hour Holter ECG recordings per patient.
- Developed parameters 'r' and 'R' to quantify VPB reduction over time.
Main Results:
- VPB frequency reduction typically occurred within 1 hour and lasted over 4 hours post-administration.
- Simultaneous high values for both 'r' and 'R' (>= -50%) were not observed.
- A majority of patients showed 'r' and 'R' values >= -50%, classifying them as responders.
- Positive test results demonstrated good predictive value for chronic treatment response.
Conclusions:
- The developed statistical model provides a reliable method for evaluating acute antiarrhythmic drug effects.
- The model aids in classifying patients as responders based on VPB reduction.
- This approach improves the assessment of antiarrhythmic therapy efficacy in patients with organic heart disease.
Abstract:
There are no reliable criteria for the evaluation of acute effects after oral application of a high single dose of an antiarrhythmic agent from the analysis of data of 46 patients with frequent complex VPBs suffering from severe organic heart disease (19 CHD, 27 COCM), we developed a new statistical model. Our calculations were based on nine 10 h Holter ECGs (2 controls, 1 placebo test, 6 class 1 antiarrhythmic agent tests) and two 24 h Holter ECGs (1 control, 1 while on chronic treatment) recorded in each patient. Usually reductions in VPB frequency caused by the medication occurred within 1 hour after application and lasted greater than or equal to 4 hours. The VPB reduction in the course of time was assessed by the parameters r and R (r = VPB reduction of the 4 h interval in comparison to the last hour before application, R = VPB reduction of the 4 h interval in comparison with an analogous interval of a control day). Values of r and R greater than or equal to -50% were never observed simultaneously. In contrast, the majority of all patients developed r and R values greater than or equal to -50% after application of an antiarrhythmic agent, and were classified as responders. As shown at a Holter control after 1 week of chronic treatment, the predictive value of a positive test result was good.